Biohaven Reports Q3 GAAP EPS Miss of $0.08
Biohaven (BHVN) reported third-quarter GAAP earnings per share of -$0.86, missing analyst expectations by $0.08. As of September 30, 2026, the company held approximately $164.0 million in cash, cash equivalents, marketable securities, and restricted cash. Despite the earnings miss, Biohaven secured significant upcoming liquidity through partnership agreements. The company received $80.0 million from Ono Pharmaceuticals on October 20, 2026, and is slated to receive an additional $350.0 million from SKBP.
Tickers: $BHVN
Topics: cash position EPS miss partnership payments quarterly earnings